PCM
CHRS icon

Penserra Capital Management’s Coherus Oncology CHRS Stock Holding History

Penserra Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,750
Closed -$28K – 1398
2021
Q3 		$28K Buy
1,750
+25
+1% +$366 ﹤0.01% 1195
2021
Q2 		$23K Buy
1,725
+70
+4% +$991 ﹤0.01% 1122
2021
Q1 		$24K Hold
1,655
– – ﹤0.01% 937
2020
Q4 		$28K Buy
1,655
+1,045
+171% +$18.6K ﹤0.01% 797
2020
Q3 		$11K Buy
+610
New +$11.3K ﹤0.01% 805
2019
Q4 		– Sell
-17,757
Closed -$359K – 889
2019
Q3 		$359K Buy
+17,757
New +$355K 0.03% 350

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Penserra Capital Management's CHRS Position: Q4 2021 in Review

Penserra Capital Management sold out of Coherus Oncology (CHRS) in Q4 2021, closing a stake of 1,750 shares — an estimated $28K sold.

Penserra Capital Management first reported a position in CHRS in Q3 2019 and held it in 6 quarters. The position peaked at $359K in Q3 2019. 201 funds tracked by Wall St. Rank hold CHRS as of Q4 2021.

  • Penserra Capital Management reported no remaining Coherus Oncology position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,750 Coherus Oncology shares in Q4 2021, an estimated $28K.
  • Penserra Capital Management first reported a position in Coherus Oncology in Q3 2019 and held it in 6 quarters.
  • Penserra Capital Management's Coherus Oncology position peaked at $359K in Q3 2019.
  • 201 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.